Gut-homing lymphocytes that express the integrin α4β7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin α4β7, is used to treat patients with inflammatory bowel diseases (IBD), but there are few data on its efficacy in patients with PSC. We investigated the effects of vedolizumab in a large international cohort of patients with PSC and IBD.

Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases / Lynch, Kate D; Chapman, Roger W; Keshav, Satish; Montano-Loza, Aldo J; Mason, Andrew L; Kremer, Andreas E; Vetter, Marcel; de Krijger, Manon; Ponsioen, Cyriel Y; Trivedi, Palak; Hirschfield, Gideon; Schramm, Christoph; Liu, Chung Heng; Bowlus, Christopher L; Estes, Derek J; Pratt, Daniel; Hedin, Charlotte; Bergquist, Annika; de Vries, Annemarie C; Janneke van der Woude, C; Yu, Lei; Assis, David N; Boyer, James; Ytting, Henriette; Hallibasic, Emina; Trauner, Michael; Marschall, Hanns-Ulrich; Daretti, Luigi M; Marzioni, Marco; Yimam, Kidist K; Perin, Nicola; Floreani, Annarosa; Beretta-Piccoli, Benedetta Terziroli; Rogers, Jennifer K; Levy, Cynthia. - In: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. - ISSN 1542-3565. - (2020). [10.1016/j.cgh.2019.05.013]

Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases

Daretti, Luigi M
;
Marzioni, Marco
;
2020-01-01

Abstract

Gut-homing lymphocytes that express the integrin α4β7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin α4β7, is used to treat patients with inflammatory bowel diseases (IBD), but there are few data on its efficacy in patients with PSC. We investigated the effects of vedolizumab in a large international cohort of patients with PSC and IBD.
2020
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/276879
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 63
  • ???jsp.display-item.citation.isi??? 61
social impact